A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have Alzheimer’s disease (AD) with gradual and progressive decline in memory function for greater than or equal to 6 months
Have a reliable study partner who will participate in the study to support the participant
Be males with partners of childbearing potential must agree to abide with provided contraception guidance
Participants Must Not:
Have prior central nervous system or psychiatric disease other than AD
Have history of cardiovascular or liver disorders
Be currently enrolled or intend to enroll in a clinical trial of another investigational product
Have suicidal tendencies
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo